2016
DOI: 10.1007/s12325-016-0310-0
|View full text |Cite
|
Sign up to set email alerts
|

Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Edema

Abstract: IntroductionThe aim of this study was to assess the impact of baseline characteristics on visual outcome of patients with diabetic macular edema and compare the results of clinical trials with different patient populations.MethodsA model was created with patient-level data from the RESPOND/RESTORE trials to estimate the impact of baseline characteristics on increases in best-corrected visual acuity (BCVA) with anti-vascular endothelial growth factor therapies, measured by letters gained on the Early Treatment … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2018
2018
2018
2018

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 18 publications
(31 reference statements)
0
1
0
Order By: Relevance
“…We used two different anti-VEGFs, ranibizumab and aflibercept. Available data suggest that these two drugs are mostly similar [ 6 , 22 ]. According to the multivariate linear regression model, there was no difference between the two anti-VEGFs (Table 3 ).…”
Section: Discussionmentioning
confidence: 99%
“…We used two different anti-VEGFs, ranibizumab and aflibercept. Available data suggest that these two drugs are mostly similar [ 6 , 22 ]. According to the multivariate linear regression model, there was no difference between the two anti-VEGFs (Table 3 ).…”
Section: Discussionmentioning
confidence: 99%